Kristofer Mussar, PhD, is COO of VectorBuilder and MD of VectorBuilder GmbH, leading global operations and innovation in gene delivery. What if business leaders approached strategy the way scientists ...
Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells ...
Genmab (NASDAQ:GMAB), a biotechnology company with a market capitalization of $16.91 billion specializing in cancer ...
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of ...
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. The industry has recovered from a challenging 2024 and is ...
NBMA advocates safe biotechnology for environmental sustainability He, however, noted that Nigeria is yet to fully benefit ...
The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits. It's typically not too difficult to find a company that should perform well for the ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced ...
Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback